Henoch-schönlein purpura induced by erlotinib (Tarceva) : a case report
Erlotinib is a newly developed molecular-targeting or molecular-targeted drug with selective inhibitory activity for tyrosine kinase of the epidermal growth factor receptor. A adverse drug reactions including diarrhea, skin eruptions are considered mild. We report a case of recurrent adenocarcinoma of the lung in a 68-year-old woman who suffered from Henoch-Schönlein purpura induced by erlotinib. She received daily administration of erlotinib 150 mg as second-line chemotherapy. Her tumors decreased in size and pleural effusion disappeared, so we considered erlotinib effective. However after 3 months of treatment with erlotinib, the patient presented palpable purpuric lesions mostly located on her lower legs. We diagnosed Henoch-Schönlein purpura based on skin histological findings. Erlotinib was reduced but continued, with improvement of the eruptions. Henoch-Schönlein purpura is often accompanied by systemic manifestations, such as renal disease and arthritis, so more careful follow-up is warranted.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society - 48(2010), 1 vom: 06. Jan., Seite 81-5 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Yuba, Tatsuya [VerfasserIn] |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 26.03.2010 Date Revised 03.12.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM195164679 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM195164679 | ||
| 003 | DE-627 | ||
| 005 | 20231223202216.0 | ||
| 007 | tu | ||
| 008 | 231223s2010 xx ||||| 00| ||jpn c | ||
| 028 | 5 | 2 | |a pubmed24n0651.xml |
| 035 | |a (DE-627)NLM195164679 | ||
| 035 | |a (NLM)20163028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Yuba, Tatsuya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Henoch-schönlein purpura induced by erlotinib (Tarceva) |b a case report |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2010 | ||
| 500 | |a Date Revised 03.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Erlotinib is a newly developed molecular-targeting or molecular-targeted drug with selective inhibitory activity for tyrosine kinase of the epidermal growth factor receptor. A adverse drug reactions including diarrhea, skin eruptions are considered mild. We report a case of recurrent adenocarcinoma of the lung in a 68-year-old woman who suffered from Henoch-Schönlein purpura induced by erlotinib. She received daily administration of erlotinib 150 mg as second-line chemotherapy. Her tumors decreased in size and pleural effusion disappeared, so we considered erlotinib effective. However after 3 months of treatment with erlotinib, the patient presented palpable purpuric lesions mostly located on her lower legs. We diagnosed Henoch-Schönlein purpura based on skin histological findings. Erlotinib was reduced but continued, with improvement of the eruptions. Henoch-Schönlein purpura is often accompanied by systemic manifestations, such as renal disease and arthritis, so more careful follow-up is warranted | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Quinazolines |2 NLM | |
| 650 | 7 | |a Erlotinib Hydrochloride |2 NLM | |
| 650 | 7 | |a DA87705X9K |2 NLM | |
| 700 | 1 | |a Nagata, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Okano, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Hatsuse, Mayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Morihara, Kiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shimazaki, Chihiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society |d 1998 |g 48(2010), 1 vom: 06. Jan., Seite 81-5 |w (DE-627)NLM095441913 |x 1343-3490 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2010 |g number:1 |g day:06 |g month:01 |g pages:81-5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2010 |e 1 |b 06 |c 01 |h 81-5 | ||